Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma

To compare overall survival in high-risk patients with primary uveal melanoma who received adjuvant sunitinib with institutional controls.

Source: Ophthalmology - September 18, 2017 Category: Opthalmology Authors: Matias E. Valsecchi, Marlana Orloff, Rino Sato, Inna Chervoneva, Carol L. Shields, Jerry A. Shields, Michael J. Mastrangelo, Takami Sato Source Type: research